FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy
The FDA said Wednesday that it is investigating “serious risk of hematologic malignancy” following the administration of bluebird bio’s Skysona, a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
